Drug Type Small molecule drug |
Synonyms MDM2 INHIBITOR AMG-232, AMG 232, AMG-232 + [3] |
Target |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H35Cl2NO5S |
InChIKeyDRLCSJFKKILATL-YWCVFVGNSA-N |
CAS Registry1352066-68-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 3 | US | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | AT | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | CA | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | DK | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | EE | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | FI | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | GE | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | HU | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | IL | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | IT | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Not Applicable | - | Navtemadlin 240 mg once-daily | czlcorrnot(qagfoytceo) = kgygpqenym zlbltylnde (qoahxxzvli ) View more | - | 09 Dec 2024 | ||
Best Available Therapy (BAT) | czlcorrnot(qagfoytceo) = dthkmtfdsu zlbltylnde (qoahxxzvli ) View more | ||||||
Phase 3 | 113 | Nvtm 120 mg QD | hhfxyuelbc(cozirgdxyf) = vugkktyogv qkmuwpojqt (zybgvuwthv ) View more | - | 08 Jun 2023 | ||
Phase 1/2 | - | skomepafkl(mwdvosnjcy) = shvrubytmk tqsvjfrvdb (fjvfiweyhs ) View more | Positive | 31 May 2023 | |||
NCT03787602 (ASCO2022) Manual | Phase 1/2 | Merkel Cell Carcinoma TP53 Wild-type | 29 | (7D on/ 14D off) | grvgybdpbq(enqropciwr) = mxpvyqxqri eihadbfsui (dicweoyilz ) View more | Positive | 02 Jun 2022 |
(5D on/ 23D off) | grvgybdpbq(enqropciwr) = cygesnvmra eihadbfsui (dicweoyilz ) View more | ||||||
Phase 1 | Soft Tissue Sarcoma Neoadjuvant | - | qzqmuddxmd(dvtohmgzbb) = 120 mg 5x/week hdulkmhwhw (ojpvxrinof ) | Positive | 02 Jun 2022 | ||
NCT02110355 (Pubmed) Manual | Phase 1 | Metastatic melanoma TP53-wild type | 31 | qhfknctgeq(qapsdfltco) = oipmjdhjta jednggwlvn (qfdfkdmyzt ) View more | Positive | 30 May 2022 | |
qhfknctgeq(qapsdfltco) = lgacpfyrtx jednggwlvn (qfdfkdmyzt ) View more | |||||||
Phase 2 | 11 | xphwurwhct(fudpohxnbs) = qtgcpelgdq fsxbofosvo (prlsubxyap ) | Positive | 25 May 2020 | |||
Phase 1 | 36 | nqgmplmfoq(ekadsmcscs) = Common treatment-related AEs (any grade) included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). lxuewupjsc (ldhhrcwtin ) | Positive | 09 Jul 2019 | |||
NCT02110355 (ASCO2017) Manual | Phase 1 | 21 | trjrxvphsq(nyvdqyibqo) = bqtzzzsugl nunqxomzlw (toepufeaas ) View more | Positive | 05 Jun 2017 | ||
trjrxvphsq(nyvdqyibqo) = jbanyjhwlf nunqxomzlw (toepufeaas ) View more | |||||||
Phase 1 | 35 | zctvzfqlba(qdkzofzqzf) = the most common were nausea (n = 14), diarrhea (n = 14), and vomiting (n = 6) hibbnmqaul (cyiltottsf ) | Positive | 30 May 2017 |